Comparative Pharmacology
Head-to-head clinical analysis: NUTROPIN AQ NUSPIN versus SEROSTIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUTROPIN AQ NUSPIN versus SEROSTIM.
NUTROPIN AQ NUSPIN vs SEROSTIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK-STAT signaling pathway, leading to increased IGF-1 production and promotion of linear growth, protein synthesis, and lipolysis.
SEROSTIM is a recombinant human growth hormone that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathways, leading to increased production of insulin-like growth factor 1 (IGF-1). It promotes linear growth, protein synthesis, and lipolysis.
Subcutaneous injection 0.16-0.24 mg/kg/week divided into 6-7 daily doses.
0.1 mg/kg subcutaneously once daily for 4 weeks; alternatively, 4 mg subcutaneously once daily for 4 weeks for patients ≥35 kg.
None Documented
None Documented
Terminal half-life: 3.9–4.3 hours (subcutaneous); supports daily dosing
Terminal half-life of approximately 2-3 hours after subcutaneous administration; prolonged in renal impairment (up to 6-8 hours).
Renal: >90% as intact peptide; minor biliary/fecal elimination (<5%)
Primarily renal (90% metabolized in liver and kidneys; 0.1% excreted unchanged in urine); biliary/fecal negligible.
Category C
Category C
Growth Hormone
Growth Hormone